secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107278
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics Q2 net loss narrows to $6.5M; Chagas Phase 1 dosing underway; cash runway into 2028
--------------------------------------------------------------------------------

- Net loss of $6.5M vs $14.4M in Q2 2024; R&D expenses down to $3.2M from $12.1M.
- Cash, cash equivalents, and investments of $71.2M; operations funded into 2028.
- Phase 1 FIH trial for Chagas drug AN2-502998 dosing started; Phase 2 planned for 2026.
- Melioidosis observational study showed ~40% 90-day mortality; seeking U.S. government funding for Phase 2.
- Two oncology development candidates (ENPP1 and PI3Kα) expected within 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017025107278/0000950170-25-107278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017025107278/antx-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer